The therapeutic potential of cannabinoids for movement disorders.
Identifieur interne : 000029 ( Main/Exploration ); précédent : 000028; suivant : 000030The therapeutic potential of cannabinoids for movement disorders.
Auteurs : Benzi Kluger [États-Unis] ; Piera Triolo ; Wallace Jones ; Joseph Jankovic [États-Unis]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2015.
Abstract
There is growing interest in the therapeutic potential of marijuana (cannabis) and cannabinoid-based chemicals within the medical community and, particularly, for neurological conditions. This interest is driven both by changes in the legal status of cannabis in many areas and increasing research into the roles of endocannabinoids within the central nervous system and their potential as symptomatic and/or neuroprotective therapies. We review basic science as well as preclinical and clinical studies on the therapeutic potential of cannabinoids specifically as it relates to movement disorders. The pharmacology of cannabis is complex, with over 60 neuroactive chemicals identified to date. The endocannabinoid system modulates neurotransmission involved in motor function, particularly within the basal ganglia. Preclinical research in animal models of several movement disorders have shown variable evidence for symptomatic benefits, but more consistently suggest potential neuroprotective effects in several animal models of Parkinson's (PD) and Huntington's disease (HD). Clinical observations and clinical trials of cannabinoid-based therapies suggests a possible benefit of cannabinoids for tics and probably no benefit for tremor in multiple sclerosis or dyskinesias or motor symptoms in PD. Data are insufficient to draw conclusions regarding HD, dystonia, or ataxia and nonexistent for myoclonus or RLS. Despite the widespread publicity about the medical benefits of cannabinoids, further preclinical and clinical research is needed to better characterize the pharmacological, physiological, and therapeutic effects of this class of drugs in movement disorders.
DOI: 10.1002/mds.26142
PubMed: 25649017
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000272
- to stream PubMed, to step Curation: 000272
- to stream PubMed, to step Checkpoint: 000028
- to stream Ncbi, to step Merge: 004237
- to stream Ncbi, to step Curation: 004237
- to stream Ncbi, to step Checkpoint: 004237
- to stream Main, to step Merge: 000029
- to stream Main, to step Curation: 000029
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The therapeutic potential of cannabinoids for movement disorders.</title><author><name sortKey="Kluger, Benzi" sort="Kluger, Benzi" uniqKey="Kluger B" first="Benzi" last="Kluger">Benzi Kluger</name><affiliation wicri:level="2"><nlm:affiliation>Movement Disorders Center, Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Movement Disorders Center, Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado</wicri:regionArea><placeName><region type="state">Colorado</region></placeName></affiliation></author><author><name sortKey="Triolo, Piera" sort="Triolo, Piera" uniqKey="Triolo P" first="Piera" last="Triolo">Piera Triolo</name></author><author><name sortKey="Jones, Wallace" sort="Jones, Wallace" uniqKey="Jones W" first="Wallace" last="Jones">Wallace Jones</name></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25649017</idno><idno type="pmid">25649017</idno><idno type="doi">10.1002/mds.26142</idno><idno type="wicri:Area/PubMed/Corpus">000272</idno><idno type="wicri:Area/PubMed/Curation">000272</idno><idno type="wicri:Area/PubMed/Checkpoint">000028</idno><idno type="wicri:Area/Ncbi/Merge">004237</idno><idno type="wicri:Area/Ncbi/Curation">004237</idno><idno type="wicri:Area/Ncbi/Checkpoint">004237</idno><idno type="wicri:Area/Main/Merge">000029</idno><idno type="wicri:Area/Main/Curation">000029</idno><idno type="wicri:Area/Main/Exploration">000029</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The therapeutic potential of cannabinoids for movement disorders.</title><author><name sortKey="Kluger, Benzi" sort="Kluger, Benzi" uniqKey="Kluger B" first="Benzi" last="Kluger">Benzi Kluger</name><affiliation wicri:level="2"><nlm:affiliation>Movement Disorders Center, Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Movement Disorders Center, Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado</wicri:regionArea><placeName><region type="state">Colorado</region></placeName></affiliation></author><author><name sortKey="Triolo, Piera" sort="Triolo, Piera" uniqKey="Triolo P" first="Piera" last="Triolo">Piera Triolo</name></author><author><name sortKey="Jones, Wallace" sort="Jones, Wallace" uniqKey="Jones W" first="Wallace" last="Jones">Wallace Jones</name></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There is growing interest in the therapeutic potential of marijuana (cannabis) and cannabinoid-based chemicals within the medical community and, particularly, for neurological conditions. This interest is driven both by changes in the legal status of cannabis in many areas and increasing research into the roles of endocannabinoids within the central nervous system and their potential as symptomatic and/or neuroprotective therapies. We review basic science as well as preclinical and clinical studies on the therapeutic potential of cannabinoids specifically as it relates to movement disorders. The pharmacology of cannabis is complex, with over 60 neuroactive chemicals identified to date. The endocannabinoid system modulates neurotransmission involved in motor function, particularly within the basal ganglia. Preclinical research in animal models of several movement disorders have shown variable evidence for symptomatic benefits, but more consistently suggest potential neuroprotective effects in several animal models of Parkinson's (PD) and Huntington's disease (HD). Clinical observations and clinical trials of cannabinoid-based therapies suggests a possible benefit of cannabinoids for tics and probably no benefit for tremor in multiple sclerosis or dyskinesias or motor symptoms in PD. Data are insufficient to draw conclusions regarding HD, dystonia, or ataxia and nonexistent for myoclonus or RLS. Despite the widespread publicity about the medical benefits of cannabinoids, further preclinical and clinical research is needed to better characterize the pharmacological, physiological, and therapeutic effects of this class of drugs in movement disorders.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Colorado</li><li>Texas</li></region><settlement><li>Houston</li></settlement><orgName><li>Baylor College of Medicine</li></orgName></list><tree><noCountry><name sortKey="Jones, Wallace" sort="Jones, Wallace" uniqKey="Jones W" first="Wallace" last="Jones">Wallace Jones</name><name sortKey="Triolo, Piera" sort="Triolo, Piera" uniqKey="Triolo P" first="Piera" last="Triolo">Piera Triolo</name></noCountry><country name="États-Unis"><region name="Colorado"><name sortKey="Kluger, Benzi" sort="Kluger, Benzi" uniqKey="Kluger B" first="Benzi" last="Kluger">Benzi Kluger</name></region><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000029 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000029 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25649017
|texte= The therapeutic potential of cannabinoids for movement disorders.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25649017" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |